Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2002

View Archived Issues

Cell Therapeutics presents data on metabolism of CT-2103

LErafAON improves tumor chemotherapy effectiveness in preclinical studies

Second-generation cell cycle inhibitors with improved solubility, oral bioavailability

Taxane-based MDR reversal agents presented at AACR meeting

Data presented at AACR meeting demonstrate promise of novel family of antimitotic agents

Targeted drug delivery using A-Z-CINN Linker proved effective in breast cancer model

Dopamine stabilizer to be evaluated in schizophrenic patients

PSP-94 may have an expanded role in prostate cancer, inhibiting metastasis and hypercalcemia

Sulfonamide 5-HT6 antagonist with advantageous pharmacological profile

Synthesis and use of integrin receptor antagonists described by Pharmacia team

Pfizer presents new 5-HT reuptake inhibitors and uses thereof

New series of protein kinase inhibitors useful for cancer, neurodegenerative disorders, etc.

Abbott reveals newly synthesized PTP1B inhibitors

Potent and selective MC4 receptor agonists designed at Roche

Boehringer Ingelheim research focuses on PTK inhibitors

Monoclonal antibody-auristatin E conjugates effective in established tumors

SGN-30, a chimeric anti-CD30 MAb, in the treatment of Hodgkin's disease

MedImmune licenses cancer technologies

Abbott makes tender offer to acquire Hokuriku Seiyaku

Paxil CR launched in U.S.

Cohesion licenses PEG technology to Zycos

Telik extends TRAP collaboration with Sanwa Kagaku

MAA filed for Olux in U.K.

Patient treatment initiated in phase II trial of Aryplase in MPS VI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...